Yan Wang

Prof. Yan Wang


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2025 in Bioengineering
Verified
Journal Article
Open access
PDF file
NXNi Xiong
Ni Xiong
ZWZibo Wei
Zibo Wei
XWXuehua Wang
Xuehua Wang
YWYan Wang
Yan Wang
ZWZhaohui Wang
Zhaohui Wang
Accurate detection of cardiac arrhythmias from electrocardiogram (ECG) signals is essential for the early diagnosis of cardiovascular diseases but remains challenging due to the complex, non-linear nature of ECG waveforms. This study proposes HCTG-Net, a Hybrid CNN–Transformer Network with Gated Fusion, designed to jointly capture local morphological features and long-range temporal dependencies in ECG data. The model employs a dual-branch architecture, where a residual CNN extracts localized waveform patterns and a Transformer branch models global temporal context. A learnable gated fusion mechanism adaptively balances and integrates features from both branches at the per-dimension level. Experiments conducted on the MIT-BIH Arrhythmia Database demonstrate that HCTG-Net achieves superior performance compared with existing methods, reaching an overall accuracy of 0.9946 and F1-score of 0.9711. Visualization results show well-clustered feature distributions, confirming robust feature learning, while ablation studies verify the complementary roles of the CNN, Transformer, and fusion modules. Overall, HCTG-Net offers a powerful and adaptive framework for automatic ECG-based arrhythmia diagnosis and holds strong potential for real-time clinical and wearable healthcare applications.

30 December 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
YHYanling Huang
Yanling Huang
HLHan Li
Han Li
JXJinjie Xiong
Jinjie Xiong
XWXvehua Wang
Xvehua Wang
JLJiaxi Lv
Jiaxi Lv
YWYan Wang
Yan Wang
Ischemic heart disease remains the leading cause of cardiovascular mortality worldwide. In myocardial infarction (MI), extracellular vesicles (EVs)—particularly small EVs (sEVs)—transport therapeutic cargo such as miR-21-5p, which suppresses apoptosis, and other proteins, lipids, and RNAs that can modulate cell death, inflammation, angiogenesis, and remodeling. This review synthesizes recent mechanistic and preclinical evidence on native and engineered EVs for post-MI repair, mapping therapeutic entry points across the MI timeline (acute injury, inflammation, and healing) and comparing EV sources (stem-cell and non-stem-cell), administration routes, and dosing strategies. We highlight engineering approaches—including surface ligands for cardiac homing, rational cargo loading to enhance potency, and biomaterial depots to prolong myocardial residence—that aim to improve tropism, durability, and efficacy. Manufacturing and analytical considerations are discussed in the context of contemporary guidance, with emphasis on identity, purity, and potency assays, as well as safety, immunogenicity, and pharmacology relevant to cardiac populations. Across small- and large-animal models, EV-based interventions have been associated with reduced infarct/scar burden, enhanced vascularization, and improved ventricular function, with representative preclinical studies reporting approximately 25–45% relative reductions in infarct size in rodent and porcine MI models, despite substantial heterogeneity in EV sources, formulations, and outcome reporting that limits cross-study comparability. We conclude that achieving clinical translation will require standardized cardiac-targeting strategies, validated good manufacturing practice (GMP)-compatible manufacturing platforms, and harmonized potency assays, alongside rigorous, head-to-head preclinical designs, to advance EV-based cardiorepair toward clinical testing.

23 August 2026 in Bioengineering
Verified
Journal Article
Open access
PDF file
XWXuehua Wang
Xuehua Wang
ZWZhaohui Wang
Zhaohui Wang
YWYan Wang
Yan Wang
The substantial burden of cardiovascular disease (CVD) attributable to air pollution remains a critical public health challenge, yet its combined effect with cardiometabolic factors is not fully understood. This study leveraged data from the Global Burden of Disease Study (GBD) and the China High Air Pollutants (CHAP) database to evaluate the CVD burden attributable to air pollution, which was found to increase progressively with age. We conducted a cross-sectional analysis using baseline (2011) data from 7420 participants aged ≥ 45 years in the China Health and Retirement Longitudinal Study (CHARLS), and a prospective cohort analysis in 8792 participants followed through 2020. In the longitudinal analysis, long-term exposure to PM2.5 (HR = 1.09, 95% CI: 1.03–1.16) and PM10 (HR = 1.07, 95% CI: 1.04–1.10) was significantly associated with an elevated risk of incident CVD, whereas the association for NO2 was nominally significant (HR = 1.12, 95% CI: 1.00–1.24) and that for O3 was not statistically significant (HR = 1.08, 95% CI: 0.93–1.27). Furthermore, prolonged exposure to these pollutants was associated with a higher prevalence of hypertension, diabetes, dyslipidemia, and obesity, and with adverse levels of metabolic indicators, including the TyG, TyG-BMI, and TyG-WC indices. A random forest model showed modest discrimination for incident CVD (AUC = 0.656), identifying PM10 and PM2.5 as the most important predictors. In conclusion, long-term exposure to ambient air pollution, particularly particulate matter, is associated with an increased risk of CVD and cardiometabolic disorders in middle-aged and older Chinese adults.